Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer
NCT03429101 · Spectrum Pharmaceuticals, Inc · PHASE1 · terminated · last registry update 2021-01-15 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Dose limiting toxicity” | – | Registry record, Spectrum Pharmaceuticals, Inc |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ERBB2 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-11-24Phase 3 first posted: Seagen, a wholly owned subsidiary of Pfizer, Tucatinib + Trastuzumab (NCT05132582)
- 2021-11-09Phase 3 first posted: AstraZeneca, Trastuzumab Deruxtecan + Paclitaxel (NCT05113251)
- 2021-09-05Results posted on the registry: Dana-Farber Cancer Institute, Trastuzumab + Pertuzumab (NCT01796197)
- 2021-05-11Results posted on the registry: Dana-Farber Cancer Institute, T-DM1 + Pertuzumab (NCT02326974)
- 2021-05-05Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Trastuzumab Emtansine (NCT04873362)
- 2021-03-05Phase 3 first posted: AstraZeneca, Trastuzumab deruxtecan + Placebo (NCT04784715)
- 2021-02-05Phase 3 first posted: Hoffmann-La Roche, Trastuzumab Emtansine + Atezolizumab (NCT04740918)
- 2020-11-09Phase 3 first posted: Daiichi Sankyo, DS-8201a + T-DM1 (NCT04622319)
- 2020-08-17Phase 3 first posted: BioRay Pharmaceutical Co., Ltd., HS627 + Pertuzumab (NCT04514419)
- 2020-07-07Phase 3 first posted: Alliance for Clinical Trials in Oncology, Trastuzumab Emtansine + Placebo Administration (NCT04457596)
- 2020-02-17Results posted on the registry: Daiichi Sankyo, DS-8201a (NCT03248492)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision